The hidden cost of weight-loss drugs: scurvy, anaemia, bleeding gums

Coverage highlights a growing concern over nutrient deficiencies—including scurvy, anemia, and bleeding gums—among users of GLP-1 weight-loss drugs like Wegovy and semaglutide. The medications, which suppress appetite, are linked to reduced intake of essential vitamins and minerals, particularly vitamin C, iron, and B12. Experts emphasize the need for targeted dietary adjustments, such as increased fiber and nutrient-dense foods, to mitigate risks while maintaining weight-loss benefits.

Major outlets including *The Times*, *NutraIngredients.com*, and *FoodNavigator.com* are focusing on dietary strategies to support GLP-1 therapy, with some publications framing the issue as a broader equity challenge. *Healthcare Today* notes disparities in access to both drugs and nutritional guidance, while *Hospital Healthcare Europe* reports on clinical studies showing semaglutide’s effectiveness even in patients with suboptimal bariatric surgery outcomes. Meanwhile, *VRT* covers Belgium’s refusal to publicly fund Wegovy, raising questions about affordability and long-term health management. Watch for deeper discussions on clinical guidelines for monitoring deficiencies in GLP-1 users, potential policy shifts in drug reimbursement, and industry responses to emerging dietary solutions.

Coverage may also expand to include patient testimonials and long-term studies on the balance between weight loss and nutritional health.